Скачать с ютуб Cenobamate & Refractory Epilepsy: A New Treatment for Focal Seizures в хорошем качестве

Cenobamate & Refractory Epilepsy: A New Treatment for Focal Seizures

Approximately 30% of epilepsy patients are considered refractory, or resistant to current treatment options. Therefore, the development of new and improved anti-epileptic drugs is of the utmost importance, each with specific mechanisms of action that target the cause of different types of epilepsies. Cenobamate (XCOPRI ®) is the latest approved antiepileptic drug in focal epilepsy blocking voltage-gated sodium channels and interaction with the GABAergic system In this webinar, you will learn how what is known about how cenobamate interacts with GABAergic system to prevent seizure activity, why it is safe and effective treatment for partial-onset epilepsy, as well as the potential side effects patients and caregivers should be made aware of when considering this treatment option. This webinar is presented by Dr. Michael Sperling, the Baldwin Keyes Professor of Neurology and Vice Chairman for Clinical Affairs in the Department of Neurology at Thomas Jefferson University in Philadelphia, PA. He is the Director of the Jefferson Comprehensive Epilepsy Center and the Clinical Neurophysiology Laboratory at Thomas Jefferson University Hospital. His primary research interests include surgical treatment of epilepsy, mortality in epilepsy, epilepsy genetics, and clinical neurophysiology.